Physician profile
Laurie Sicard
NPI 1821220591
$6,900.04
in general payments reported to CMS, 2019-2025
25 companies · $950 in 2025
The $950 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,318 · 2020: $378 · 2021: $717 · 2022: $869 · 2023: $888 · 2024: $779 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561 · Entertainment: $55.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.85 |
| Entertainment | $55.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,434.98 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Glaukos Corporation | $778.43 | 2020-2025 | Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Allergan, INC. | $767.55 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $653.38 | 2019-2024 | Cequa |
| Abbvie INC. | $639.77 | 2022-2025 | Durysta, Lumigan, Vuity |
| Biotissue Holdings INC. | $430.17 | 2019-2025 | |
| Oyster Point Pharma, INC. | $401.23 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $346.20 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $297.87 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $131.28 | 2021-2023 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $110.84 | 2023 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Shire North American Group INC | $107.84 | 2019 | |
| Optos, INC. | $101.86 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $100.14 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $94.19 | 2023-2025 | Xiidra, Miebo, Vyzulta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $84.80 | 2019-2021 | |
| Coopervision INC. | $77.81 | 2019 | |
| Ivantis, INC | $66.74 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $60.84 | 2021 | |
| Dompe US, INC. | $60.22 | 2025 | Oxervate |
| Lkc Technologies, INC. | $56.44 | 2023 | |
| Eyevance Pharmaceuticals LLC | $30.29 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $24.98 | 2021 | |
| Harrow Eye, LLC | $23.36 | 2024 | Vevye |
| Johnson & Johnson Vision Care, INC. | $18.83 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Sicard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.